



DEPARTMENT OF HEALTH & HUMAN SERVICES

New York District

Food & Drug Administration
158 - 15 Liberty Avenue
Jamaica, New York 11433-1034

1/22/01

WARNING LETTER

February 26, 2001

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

REF: NYK-2001-47

Cheryl Jean Byk, M.D.
Radiologist / Lead Interpreting Physician
Gramercy Radiology Group, P. C.
201 East 19th Street
New York, New York 10003

Facility ID: #114421

Dear Dr. Byk:

Your facility was inspected on February 8th, 2001 by a representative of the New York City Department of Health, Bureau of Radiological Health, acting on behalf of the U. S. Food & Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography operation at your facility. Under a United States Federal Law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography operations. These requirements help protect the Health of women by assuring that a facility can perform quality mammography procedures.

The inspection revealed the following repeat Level 2(R) noncompliance finding at your facility:

- 1. Seven (7) of ten (10) random reports reviewed did not contain an assessment category for the site.***

The specific problem noted above appeared on your MQSA Facility Inspection Report which was issued to your facility at the close of the inspection. This problem is identified as a repeat Level 2 (R) noncompliances, because it identifies a failure to meet a significant MQSA requirement and indicates failure by your facility to implement permanent correction of the problem found.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a violation of the law which may result in FDA taking regulatory action without further notice to you.

Gramercy Radiology Group, P. C. - February 21, 2001

Warning Letter – NYK-2001-47

Page #2

These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.


It is necessary for you to act on these matters immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:

- *The specific steps you have taken to correct the violation noted in this letter;*
- *Each step your facility is taking to prevent the recurrence of similar violations; and*
- *Sample records that demonstrate proper record keeping procedures.*

Please submit your response to the above issues to the attention of Arthur S. Williams, Jr., Compliance Officer, U. S. Food & Drug Administration (FDA), 158 - 15 Liberty Avenue, Jamaica, New York 11433-1034, Tel.: (718)/662-5568.

Finally, you should understand there are many FDA requirements pertaining to mammography. This letter pertains only to findings of our inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, U. S. Food and Drug Administration (FDA), P.O. Box 6057, Columbia, Maryland 21045-6057, Tel.: 1(800)/838-7715, or through the Internet at <http://www.fda.gov>.

Sincerely yours,



Jerome G. Woyshner
Acting District Director
New York District